1. Calvert A.H., Newell D.R., Jackman A.L., Gumbrell L.A., Sikora E., Grzelakowska-Sztabert B., Bishop J.A.M., Judson I.R., Harland S.J. and Harrap K.R., 1987, Recent Preclinical and Clinical Studies with the Thymidylate Synthase Inhibitor N10-Propargyl-5,8-dideazafolic acid (CB 3717), NCI Monographs, 5:213–218.
2. D1694_-See Jackman A.L. in this volume.
3. -See Beardsley G.P. in this volume.
4. Grindey, G. B., Alati, T., and Shih, C. Reversal of the Toxicity, but not the Antitumour Activity of Lometrexol by Folic Acid. Proc. Amer. Assoc. Cancer Res. 1991 Abs 1921.
5. Kris M.G., Kinaham J.J., Gralla R.J., Fanucchi M.P., Wertheim M.S., O’Connell J.P., Marks L.D., Williams L., Farag F., Young C.W. and Sirotnak F.M., 1988, Phase I Trial and Clinical Pharmacological Evaluation of 10-Ethyl-10-deazaaminopterin in Adult Patients. Cancer Res., 48:5573–5579.